Publication Name	World Journal of Gastrointestinal Surgery
Manuscript ID	28751
Country	Canada

Received	2016-08-04 17:23
Peer-Review Started	2016-08-05 11:49
To Make the First Decision	2016-08-26 08:16
Return for Revision	2016-08-29 16:59
Revised	2016-09-07 12:37
Second Decision	2016-09-28 11:25
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-10-18 17:14
Articles in Press	2016-10-18 17:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-12-15 09:55
Publish the Manuscript Online	2016-12-20 13:39

ISSN	1948-9366 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia
Manuscript Source	Unsolicited Manuscript
All Author List	George Ou, Cherry Galorport and Robert Enns
Funding Agency and Grant Number
Corresponding Author	Robert Enns, MD, FRCPC, Division of Gastroenterology, Department of Medicine, St. Paul’s Hospital, University of British Columbia, Suite 770 - 1190 Hornby Street, Vancouver, BC V6Z 1Y6, Canada. rob.enns@ubc.ca
Key Words	Bevacizumab; Vascular endothelial growth factor; Hereditary hemorrhagic telangiectasia; Bleeding; Osler-Weber-Rendu syndrome
Core Tip	Management of gastrointestinal (GI) bleeding in patients with hereditary hemorrhagic telangiectasia (HHT) can be challenging when the vascular lesions recur despite repeated endoscopic treatments. There is increasing evidence supporting the use of anti-angio-genesis agents in the management of bleeding in HHT patients. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to reduce recurrent epistaxis. This case demonstrates the therapeutic potential of bevacizumab in patients with severe GI bleeding requiring massive transfusions.
Publish Date	2016-12-20 13:39
Citation	Ou G, Galorport C, Enns R. Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. World J Gastrointest Surg 2016; 8(12): 792-795
URL	http://www.wjgnet.com/1948-9366/full/v8/i12/792.htm
DOI	http://dx.doi.org/10.4240/wjgs.v8.i12.792

Full Article (PDF)	WJGS-8-792.pdf
Full Article (Word)	WJGS-8-792.doc
Manuscript File	28751-Review.docx
Answering Reviewers	28751-Answering reviewers.pdf
Audio Core Tip	28751-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	28751-Conflict-of-interest statement.pdf
Copyright License Agreement	28751-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	Informed_Consent_Statement_20160804131825.docx
Institutional Review Board Approval Form or Document	28751-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	Editing_Certificate_20160713150135.docx
Peer-review Report	28751-Peer-review(s).pdf
Scientific Misconduct Check	28751-Scientific misconduct check.pdf
Scientific Editor Work List	28751-Scientific editor work list.pdf